Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2020-10-08
Target enrollment:
Participant gender:
Summary
Open-label, long-term safety study of ARQ-151 cream 0.3% in subjects with chronic plaque
psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied
by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits
will include assessments for clinical safety, application site reactions, and disease
improvement or progression.